Friday, November 21, 2008

CRO BioReliance Enters Tech-Development

From Proteo Monitor:


Contract research organization BioReliance this month launched a new array service for the screening of non-human antigens in animal serum, the first fruit of a new technology-development strategy the company embarked upon after being sold by Invitrogen last year

The array platform, called ReliArray, currently in beta testing and available only to select customers, will formally debut in January, replacing the ELISA technology currently being used by BioReliance for serological testing.

Read the rest of this article here.

No comments:

Post a Comment